Laurus Labs gets EIR from USFDA for Unit 2 at Visakhapatnam

23 Jan 2020 Evaluate

Laurus Labs has received an Establishment Inspection Report (EIR) (for the Pre-Approval Inspection) from US Food and Drug Administration (USFDA) for its Unit-2 (FDF&API integrated facility) located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

The Pre-Approval Inspection (PAI) was carried out from November 04, 2019 to November 08, 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1025.95 13.30 (1.31%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×